Lupin Limited has announced a strategic move to strengthen its gastroenterology portfolio by entering into an exclusive licensing agreement with Italy-based pharmaceutical company Neopharmed Gentili S.p.A. The agreement has been signed through Lupin’s subsidiaries—Multicare Pharmaceuticals in the Philippines and MedQuimica in Brazil—and covers the marketing and promotional rights for the gastroenterology brand Plasil® (metoclopramide) in these two key emerging markets.
Under the terms of the agreement, Lupin will market and promote Plasil® in the Philippines and Brazil, while Neopharmed Gentili will manage product supply for the Philippine market, ensuring adherence to global quality and compliance standards. In Brazil, manufacturing of the product will be transitioned to MedQuimica’s local production facility, further strengthening Lupin’s operational footprint in the region.
Plasil®, a well-established metoclopramide-based therapy, is widely used in the treatment of nausea and vomiting and is considered a potent anti-emetic option in gastroenterology care. By adding Plasil® to its portfolio, Lupin aims to deepen its presence in the gastroenterology segment while expanding access to trusted treatments across high-growth emerging markets.
Commenting on the development, Fabrice Egros, President of Corporate Development at Lupin, said that the partnership marks an important milestone in the company’s efforts to expand patient access to Plasil® across the Philippines and Brazil. He highlighted that Lupin’s strong local presence, regulatory expertise, and commercial capabilities, combined with Neopharmed Gentili’s distribution strength and market reach, will help deliver meaningful health outcomes for patients.
